AbbVie Inc. closed 5.34% below its 52-week high of $207.32, which the company reached on October 31st.

AbbVie just rewarded its shareholders again with a dividend. This stock has boosted its payout annually for more than 50 ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...

In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global ...

AbbVie Inc. offers a combination of rock-solid business mix, aggressive growth strategy, and shareholder-friendly capital allocation. The company holds strong positions in rapidly growing markets ...

AbbVie has entered a partnership and option-to-license agreement with Xilio for tumour-activated, antibody-based ...

Feb. 13, 2025 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ... 2025. Since the company's inception in 2013, AbbVie has increased its dividend by 310 percent.

The North Chicago drugmaker says it could pay Xilio Therapeutics more than $2.1 billion in a collaboration and ...